



## For Immediate Release

### Symic Receives New U.S. Patent for Osteoarthritis Program

*- New Patent Strengthens Symic's Proprietary Position of Using Synthetic Proteoglycans for Therapies -*

**SAN FRANCISCO, Dec. 16, 2015** – Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it continues to fortify the patent protection covering its proteoglycan-based therapeutic platform with U.S. Patent No 9,217,016, which will be issued on Dec. 22, 2015. This patent covers SB-061, a compound that mimics the protective proteoglycan, aggrecan, to reduce cartilage degradation and pain in patients with osteoarthritis (OA).

“This patent, our fourth in the U.S., further demonstrates our leadership in developing proteoglycan-based therapeutic compounds,” said Ken Horne, Chief Executive Officer of Symic. “This particular patent provides coverage for proteoglycan mimetics that bind to hyaluronic acid, which can reduce pain and prevent the degradation of cartilage in patients suffering from osteoarthritis. We have also recently received patent protection for proteoglycan mimetics that bind collagen, as well as protection for many of the uses of these technologies in the treatment of disease.”

Symic’s primary technology was developed at the Purdue University Weldon School of Biomedical Engineering in the laboratory of Alyssa Panitch, Ph.D., the Leslie A. Geddes Professor of Biomedical Engineering and a founder and scientific advisory board member of Symic.

#### **About Symic**

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic’s proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. SB-030 is Symic’s lead compound under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury.

Symic is based in San Francisco. For additional information, please visit the company’s website at <http://www.symic.bio> or follow us on Twitter at [www.twitter.com/symicbio](http://www.twitter.com/symicbio) and LinkedIn at [www.linkedin.com/company/symic-bio/](http://www.linkedin.com/company/symic-bio/).

###

**Media Contacts**

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[lena.evans@russopartnersllc.com](mailto:lana.evans@russopartnersllc.com)